Nature Structural and Molecular Biology, volume 25, issue 6, pages 454-462

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors

Rasmus Hansen 1
Ulf Peters 1
Anjali Babbar 1
Yuching Chen 1
Jun Feng 1
Matthew R. Janes 1
Lian-Sheng Li 1
Pingda Ren 1, 2
Yi Liu 1, 2
Patrick P Zarrinkar 1
1
 
Wellspring Biosciences, Inc., San Diego, USA
2
 
Kura Oncology, Inc., San Diego, USA
Publication typeJournal Article
Publication date2018-05-14
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor16.8
ISSN15459993, 15459985
Molecular Biology
Structural Biology
Abstract
Activating mutations in KRAS are among the most common tumor driver mutations. Until recently, KRAS had been considered undruggable with small molecules; the discovery of the covalent KRASG12C inhibitors ARS-853 and ARS-1620 has demonstrated that it is feasible to inhibit KRAS with high potency in cells and animals. Although the biological activity of these inhibitors has been described, the biochemical mechanism of how the compounds achieve potent inhibition remained incompletely understood. We now show that the activity of ARS-853 and ARS-1620 is primarily driven by KRAS-mediated catalysis of the chemical reaction with Cys12 in human KRASG12C, while the reversible binding affinity is weak, in the hundreds of micromolar or higher range. The mechanism resolves how an induced, shallow and dynamic pocket not expected to support high-affinity binding of small molecules can nevertheless be targeted with potent inhibitors and may be applicable to other targets conventionally considered undruggable. Kinetic and structural analyses show that the activity of two covalent inhibitors of human KRASG12C, which initially bind to a shallow pocket with low affinity, is driven by KRAS-mediated catalysis of the chemical reaction with Cys12.

Top-30

Citations by journals

2
4
6
8
10
12
Journal of Medicinal Chemistry
12 publications, 11.21%
Nature Chemical Biology
4 publications, 3.74%
ACS Chemical Biology
3 publications, 2.8%
RSC Medicinal Chemistry
3 publications, 2.8%
Molecules
2 publications, 1.87%
Cancers
2 publications, 1.87%
Frontiers in Molecular Biosciences
2 publications, 1.87%
Nature
2 publications, 1.87%
Pharmacological Research
2 publications, 1.87%
ChemMedChem
2 publications, 1.87%
ChemBioChem
2 publications, 1.87%
Organic and Biomolecular Chemistry
1 publication, 0.93%
Future Medicinal Chemistry
1 publication, 0.93%
Current Pharmaceutical Design
1 publication, 0.93%
Current Molecular Pharmacology
1 publication, 0.93%
Biochemical Society Transactions
1 publication, 0.93%
Biochemical Journal
1 publication, 0.93%
SAR and QSAR in Environmental Research
1 publication, 0.93%
Anti-Cancer Drugs
1 publication, 0.93%
Journal of Chemical Information and Modeling
1 publication, 0.93%
Biomedicines
1 publication, 0.93%
Frontiers in Cell and Developmental Biology
1 publication, 0.93%
Journal of Hematology and Oncology
1 publication, 0.93%
Journal of Molecular Modeling
1 publication, 0.93%
Signal Transduction and Targeted Therapy
1 publication, 0.93%
Nature Biotechnology
1 publication, 0.93%
Cell Discovery
1 publication, 0.93%
Cancer and Metastasis Reviews
1 publication, 0.93%
Nature Structural and Molecular Biology
1 publication, 0.93%
2
4
6
8
10
12

Citations by publishers

5
10
15
20
25
American Chemical Society (ACS)
22 publications, 20.56%
Elsevier
19 publications, 17.76%
Springer Nature
16 publications, 14.95%
Wiley
11 publications, 10.28%
Cold Spring Harbor Laboratory
8 publications, 7.48%
Multidisciplinary Digital Publishing Institute (MDPI)
6 publications, 5.61%
Royal Society of Chemistry (RSC)
5 publications, 4.67%
Taylor & Francis
3 publications, 2.8%
Frontiers Media S.A.
3 publications, 2.8%
Bentham Science
2 publications, 1.87%
Portland Press
2 publications, 1.87%
American Society of Clinical Oncology (ASCO)
2 publications, 1.87%
Future Medicine
1 publication, 0.93%
Wolters Kluwer Health
1 publication, 0.93%
SAGE
1 publication, 0.93%
American Society for Biochemistry and Molecular Biology
1 publication, 0.93%
American Association for Cancer Research (AACR)
1 publication, 0.93%
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 0.93%
Rockefeller University Press
1 publication, 0.93%
Hans Publishers
1 publication, 0.93%
5
10
15
20
25
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Hansen R. et al. The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors // Nature Structural and Molecular Biology. 2018. Vol. 25. No. 6. pp. 454-462.
GOST all authors (up to 50) Copy
Hansen R., Peters U., Babbar A., Chen Y., Feng J., Janes M. R., Li L., Ren P., Liu Y., Zarrinkar P. P. The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors // Nature Structural and Molecular Biology. 2018. Vol. 25. No. 6. pp. 454-462.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1038/s41594-018-0061-5
UR - https://doi.org/10.1038/s41594-018-0061-5
TI - The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
T2 - Nature Structural and Molecular Biology
AU - Hansen, Rasmus
AU - Peters, Ulf
AU - Babbar, Anjali
AU - Chen, Yuching
AU - Feng, Jun
AU - Janes, Matthew R.
AU - Li, Lian-Sheng
AU - Ren, Pingda
AU - Liu, Yi
AU - Zarrinkar, Patrick P
PY - 2018
DA - 2018/05/14 00:00:00
PB - Springer Nature
SP - 454-462
IS - 6
VL - 25
SN - 1545-9993
SN - 1545-9985
ER -
BibTex |
Cite this
BibTex Copy
@article{2018_Hansen,
author = {Rasmus Hansen and Ulf Peters and Anjali Babbar and Yuching Chen and Jun Feng and Matthew R. Janes and Lian-Sheng Li and Pingda Ren and Yi Liu and Patrick P Zarrinkar},
title = {The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors},
journal = {Nature Structural and Molecular Biology},
year = {2018},
volume = {25},
publisher = {Springer Nature},
month = {may},
url = {https://doi.org/10.1038/s41594-018-0061-5},
number = {6},
pages = {454--462},
doi = {10.1038/s41594-018-0061-5}
}
MLA
Cite this
MLA Copy
Hansen, Rasmus, et al. “The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors.” Nature Structural and Molecular Biology, vol. 25, no. 6, May. 2018, pp. 454-462. https://doi.org/10.1038/s41594-018-0061-5.
Found error?